**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 37-year-old woman developed DRESS syndrome after empirical treatment with hydroxychloroquine.

The woman presented with facial oedema, itchy rash and fever for the past 2 days. Physical examination showed a maculopapular rash (predominantly on the face), periorbital angioedema and purpuric rash with involvement of the limbs (no involvement of soles and palms) and trunk. Bilateral cervical lymphadenopathy and oral mucosa enanthema were present. Further investigations showed that she had received empirical therapy with hydroxychloroquine 200mg \[*route and frequency not stated*\] and lopinavir/ritonavir and azithromycin due to the suspicion of COVID-19. Laboratory findings demonstrated leucocytosis with eosinophilia and increased transaminases. Abdominal ultrasound was unremarkable. Further findings showed positive results for cytomegalovirus, Epstein-Barr virus, chickenpox, parvovirus B-19 and measles \[*aetiologies not stated*\]. However, SARS-CoV-2 was negative. After 8 weeks, patch tests (each 20% water and petrolatum) with hydroxychloroquine, lopinavir/ritonavir and azithromycin were performed, which showed positive result for hydroxychloroquine on day 4. Further, DRESS syndrome secondary to hydroxychloroquine was diagnosed as per the RegiSCAR group criteria \[*time to reaction onset and outcome not stated*\].
